PepGen Inc. (PEPG) company profile
Close on Nov 13, 2026Market cap $301.97MP/E –Yield –
About PepGen
Pharmaceutical Preparations, SIC 2834
PepGen Inc. is a clinical-stage biotechnology company that develops oligonucleotide therapeutics for severe neuromuscular and neurologic disorders. The company utilizes an Enhanced Delivery Oligonucleotide platform that conjugates cell-penetrating peptides with synthetic oligonucleotides to improve delivery into target cells and tissues, including skeletal and cardiac muscle. Its lead candidate, PGN-EDODM1, targets the underlying genetic defect of myotonic dystrophy type 1 by binding to toxic expanded RNA repeats to correct cellular splicing. Because the company has no approved commercial treatments, its therapeutic candidates are intended for patients living with myotonic dystrophy type 1.
The company is headquartered in Boston, Massachusetts. Its clinical activities span several countries, having conducted trials in the United States, Canada, and the United Kingdom, and received regulatory clearances to conduct studies in South Korea, Australia, and New Zealand.
Summary of the business section of PepGen's latest annual report, written by StockData.
Company profile
Company
- Legal name
- PepGen Inc.
- Headquarters
- Boston, MA
- Address
- 1 Marina Park Drive, Suite 900 02210
- Phone
- (703) 456-8000
- Website
- pepgen.com
- Employees
- 56, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, San Diego, CA, USA
Stock & identifiers
- Ticker
- PEPG
- Exchange
- Nasdaq
- IPO date
- May 9, 2022
- Shares outstanding
- 69M, Aug 2, 2026
- Public float
- $16.90M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1835597
- CUSIP
- 713317105
- ISIN
- US7133171055
- FIGI
- BBG012232618
- Share class FIGI
- BBG012232627
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| James G. McArthur | President and CEO, Director | 296,457 |
| Kasra Kasraian | Chief Technical Officer | 50,074 |
| Noel Donnelly | Chief Financial Officer | 111,603 |
| Paul Streck | EVP, Head of R&D | 76,226 |
| Joseph Vittiglio | Chief Business & Legal Officer | 65,717 |
| Mary Beth DeLena | General Counsel | 14,968 |
| Laurie Keating | Director | 4,166 |
| Joshua Resnick | Director | – |
| Capital Healthcare Fund LP RA | Director | 18,554,273 |
| Howard Mayer | Director | – |
| Lisa Wyman | Director | – |
| Mitchell H. Finer | Director | – |
| Habib J. Dable | Director | – |
| Rajeev M. Shah | Director | – |
| Peter Kolchinsky | Director | 9,179,273 |
| Ra Capital Management, L.P. | Director | – |
| RA Capital Nexus Fund II, L.P. | Director | – |
| Heidi Henson | Director | – |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|
| James McArthur President and Chief Executive Officer | $619.00K | $428.12K | $170.62K | $2.09M | $10.50K | $3.32M | -25% |
| Noel P. Donnelly Chief Financial Officer | $487.09K | $245.01K | $99.46K | $916.83K | $10.50K | $1.76M | -25% |
| Joseph D. Vittiglio Chief Business and Legal Officer | $31.23K | $244.00K | $195.65K | $732.53K | $116.41K | $1.32M | – |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- May 9, 2022
- Offer price
- $12.00
- Securities offered
- 9,000,000
- Gross proceeds
- $108.00M
- Exchange
- Nasdaq
- First trading day
- May 6, 2022
- First-day close
- $12.89+7.4%
- Lock-up ends (est.)
- Nov 2, 2022
“The initial public offering price is $12.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 56 full-time employees, of whom 17 have Ph.D.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 9, 2022 | IPO | Initial public offering priced (424B4 prospectus) |
| May 3, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?